Jump to content

Gary L. Johnson: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
formatting
m Added short description #article-add-desc
Tags: Mobile edit Mobile app edit iOS app edit
 
(25 intermediate revisions by 15 users not shown)
Line 1: Line 1:
{{Short description|American scientist and professor}}
{{Multiple issues|
{{BLP primary sources|date=July 2021}}
{{Undisclosed paid|date=June 2022}}
}}
{{Infobox academic|honorific_prefix=<!-- see [[MOS:CREDENTIAL]] and [[MOS:HONORIFIC]] -->|era=|website=|education=|alma_mater=California State University, Northridge
{{Infobox academic|honorific_prefix=<!-- see [[MOS:CREDENTIAL]] and [[MOS:HONORIFIC]] -->|era=|website=|education=|alma_mater=California State University, Northridge
University of Colorado Medical School
University of Colorado Medical School
University of California, San Francisco|thesis_title=|thesis_url=|thesis_year=|school_tradition=|doctoral_advisor=|academic_advisors=|influences=<!--must be referenced from a third-party source-->|discipline=Pharmacology, Cellular Biology,|relatives=|sub_discipline=<!--academic discipline specialist area – e.g. Sub-atomic research, 20th-century Danish specialist, Pauline research, Arcadian and Ugaritic specialist-->|workplaces=<!--full-time positions only, not student positions-->|doctoral_students=<!--only those with WP articles-->|notable_students=<!--only those with WP articles-->|main_interests=|notable_works=|notable_ideas=|influenced=<!--must be referenced from a third-party source-->|signature=|signature_alt=|signature_size=|awards=Kenan Distinguished Professor
University of California, San Francisco|thesis_title=|thesis_url=|thesis_year=|school_tradition=|doctoral_advisor=|academic_advisors=|influences=<!--must be referenced from a third-party source-->|discipline=Pharmacology, Cellular Biology,|relatives=|sub_discipline=<!--academic discipline specialist area – e.g. Sub-atomic research, 20th-century Danish specialist, Pauline research, Arcadian and Ugaritic specialist-->|workplaces=<!--full-time positions only, not student positions-->|doctoral_students=<!--only those with WP articles-->|notable_students=<!--only those with WP articles-->|main_interests=|notable_works=|notable_ideas=|influenced=<!--must be referenced from a third-party source-->|signature=|signature_alt=|signature_size=|awards=Kenan Distinguished Professor
Hyman L. Battle Distinguished Cancer Research Award|parents=|name=Gary L. Johnson|death_place=|honorific_suffix=|image=File:Gary L. Johnson.jpg|image_size=|alt=|caption=|native_name=|native_name_lang=|birth_name=<!-- use only if different from full/othernames -->|birth_date=<!-- {{birth date and age|YYYY|MM|DD}} -->|birth_place=|death_date=<!-- {{death date and age|YYYY|MM|DD|YYYY|MM|DD}} (death date then birth date) -->|death_cause=|children=|nationality=|citizenship=American|other_names=|occupation=Professor|period=|known_for=|home_town=|title=|boards=American Association for Cancer Research (AACR)|spouse=|partner=|footnotes=}}'''Gary L. Johnson''' is an American scientist and Professor recognized for his work with [[oncogene]]<nowiki/>s and [[Stem cell|stem cells]] in the fields of [[molecular pharmacology]] and [[cancer cell biology]]. His other research interests include [[Cell signaling|signaling networks]] controlling cell function and disease and the behavior of the [[Kinome|kinome en masse]] in cancer<ref name=":0">{{Cite web|title=Gary L. Johnson|url=https://unclineberger.org/directory/gary-l-johnson-phd/|access-date=2020-10-07|website=UNC Lineberger|language=en-US}}</ref>.
Hyman L. Battle Distinguished Cancer Research Award|parents=|name=Gary L. Johnson|death_place=|honorific_suffix=|image=|image_size=|alt=|caption=|native_name=|native_name_lang=|birth_name=<!-- use only if different from full/othernames -->|birth_date=<!-- {{birth date and age|YYYY|MM|DD}} -->|birth_place=|death_date=<!-- {{death date and age|YYYY|MM|DD|YYYY|MM|DD}} (death date then birth date) -->|death_cause=|children=|nationality=|citizenship=American|other_names=|occupation=Professor|period=|known_for=|home_town=|title=|boards=American Association for Cancer Research (AACR)|spouse=|partner=|footnotes=}}'''Gary L. Johnson''' is an American scientist and Professor recognized for his work with [[oncogene]]s and [[stem cell]]s in the fields of [[Molecular biology|molecular]] [[pharmacology]] and [[cancer cell]] biology. His other research interests include [[Cell signaling|signaling networks]] controlling cell function and disease and the behavior of the [[Kinome|kinome en masse]] in cancer.<ref name=":0">{{Cite web|title=Gary L. Johnson|url=https://unclineberger.org/directory/gary-l-johnson-phd/|access-date=2020-10-07|website=UNC Lineberger|language=en-US}}</ref>


Johnson is a past Kenan Distinguished Professor, chair of the [[University of North Carolina at Chapel Hill|UNC Chapel Hill]] Department of Pharmacology, and a member of the [[UNC Lineberger Comprehensive Cancer Center|UNC Lineberger Comprehensive Cancer Cente]]<nowiki/>r.
Johnson is a past Kenan Distinguished Professor, chair of the [[University of North Carolina at Chapel Hill|UNC Chapel Hill]] Department of Pharmacology, and a member of the [[UNC Lineberger Comprehensive Cancer Center]].


== Education ==
== Education ==
Johnson earned his B.A. in [[Biology]] in 1971 at [[California State University, Northridge|Cal State Northridge,]]<nowiki/>where he graduated [[Latin honors|Magna Cum Laude]], and his Ph.D. in [[Pharmacology]] in 1976 at the [[University of Colorado Medical School]]. He then completed his PostDoc in 1979 at the [[University of California, San Francisco]]. He served as the chair of the Department of Pharmacology at UNC Chapel Hill from 2003-2017 and was a Kenan Distinguished Professor from 2011-2019. During his time in education, Johnson trained over 80 postdoctoral fellows and PhD students. Now, Johnson works as the co-director of the Program in Molecular Therapeutics for the Lineberger Comprehensive Cancer Center and director of the Human Genome RNAi/CRISPR Screening Facility<ref name=":0" />.
Johnson earned his B.A. in [[Biology]] in 1971 at [[California State University, Northridge|Cal State Northridge]],where he graduated [[Latin honors|Magna Cum Laude]], and his Ph.D. in [[Pharmacology]] in 1976 at the [[University of Colorado Medical School]].<ref>{{Cite web |date=14 October 2005 |title=Gary Johnson: Speaking From Experience |url=https://www.science.org/content/article/gary-johnson-speaking-experience |access-date=2022-09-13 |website=www.science.org |language=en}}</ref> He then completed his PostDoc in 1979 at the [[University of California, San Francisco]]. He served as the chair of the Department of Pharmacology at UNC Chapel Hill from 2003 to 2017 and was a Kenan Distinguished Professor from 2011 to 2019. During his time in education, Johnson trained over 80 postdoctoral fellows and PhD students. Now, Johnson works as the co-director of the Program in Molecular Therapeutics for the Lineberger Comprehensive Cancer Center and director of the Human Genome RNAi/CRISPR Screening Facility.<ref name=":0" />


== Work ==
== Work ==
From 1994 to 1999, Johnson served as the Director of Cell Biology for Cadus Pharmaceuticals Inc. He worked four years as a consultant for Atherogenics, Inc. He was a co-founder of KinoDyn, Inc., a biotech company located in Chapel Hill, NC<ref>https://www.dnb.com/business-directory/company-profiles.kinodyn_inc.248bc02d9dcf62214e3b0d15e1457223.html</ref>.
From 1994 to 1999, Johnson served as the Director of Cell Biology for Cadus Pharmaceuticals Inc. He worked four years as a consultant for Atherogenics, Inc. He was a co-founder of KinoDyn, Inc., a biotech company located in Chapel Hill, NC.<ref>[https://www.dnb.com/business-directory/company-profiles.kinodyn_inc.248bc02d9dcf62214e3b0d15e1457223.html Company profile] dnb.com</ref>


== Research ==
== Research ==
Johnson has made many contributions to the fields of molecular pharmacology and cell biology. In the early 90s, his laboratories demonstrated that oncogenes, such as Ras and Src, activated the [[MAPK]], ERK1/2. This research defined the MAPK signaling network as part a large network of [[MAP3K]]<nowiki/>s, [[MAP2K]]<nowiki/>s, and [[MAPK]]<nowiki/>s. They defined the role MAPKs in [[proliferation]], [[apoptosis]], migration, and invasion<ref>Gallego, C., Gupta, S.K., Heasley, L.E., Qian, N.-X. and Johnson, G.L. (1992) Mitogen-activated protein kinase activation resulting from selective oncogene expression in NIH 3T3 and Rat 1a cells. Proc Natl Acad Sci USA 89, 7355-7359 PMC50199</ref>. His laboratory published 250 MAPK network related papers. His lab was one to demonstrate that [[Agonist|agonists]] targeting the same GPCR have "[[biased agonism]]" and "asymmetric signaling."<ref>Heasley, L.E., Zamarripa, J., Storey, B., Helfrich, B., Mitchell, F.M., Bunn, Jr., P.A. and Johnson, G.L. (1996) Discordant signal transduction and growth inhibition of small cell lung carcinomas induced by expression of GTPase-deficient G 16. J Biol Chem 271, 349-354 PMID: 8550585</ref> This is when agonists activate signaling pathways at different distinct intensities. In his work with stem cells, they defined a mutation that captured self-renewing tissue stem cell in a permanent state of [[EMT]]<ref>Vincent Jordan, N., Prat, A., Abell, A.N., Zawistowski, J.S., Sciaky, N., Karginova, O.A., Zhou., B, Golitz, B.T., Perou, C.M., Johnson, G.L.. (2013) SWI/SNF Chromatin-remodeling Factor Smarcd3/Baf60c Controls EMT by Inducing Wnt5a Signaling. Mol Cell Biol 33, 3011-3025. PMC3719671</ref>. The lab has also made advancements in Adaptive Kinome Programming. They defined the adaptive bypass mechanisms that result in the lack of durable responses to targeted kinase inhibitors<ref>Johnson, G.L., Stuhlmiller, T.J., Angus, S.P., Zawistowski, J.S., Graves, L.M. (2014) Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF-MEK-ERK Pathway in Cancer. Clin Cancer Res. 20: 2516-2522 PMC4024346</ref>. Overall, Johnson has over 300 published papers<ref>My Bibliography - NCBI (nih.gov)</ref>.
Johnson has made many contributions to the fields of molecular pharmacology and cell biology. In the early 90s, his laboratories demonstrated that oncogenes, such as Ras and Src, activated the [[MAPK]], ERK1/2. This research defined the MAPK signaling network as part a large network of [[MAP3K]]s, [[MAP2K]]s, and [[MAPK]]s. They defined the role MAPKs in [[Cell proliferation|proliferation]], [[apoptosis]], migration, and invasion.<ref>Gallego, C., Gupta, S.K., Heasley, L.E., Qian, N.-X. and Johnson, G.L. (1992) Mitogen-activated protein kinase activation resulting from selective oncogene expression in NIH 3T3 and Rat 1a cells. Proc Natl Acad Sci USA 89, 7355-7359 PMC50199</ref> His laboratory published 250 MAPK network related papers. His lab was one to demonstrate that [[agonist]]s targeting the same GPCR have "[[biased agonism]]" and "asymmetric signaling."<ref>Heasley, L.E., Zamarripa, J., Storey, B., Helfrich, B., Mitchell, F.M., Bunn, Jr., P.A. and Johnson, G.L. (1996) Discordant signal transduction and growth inhibition of small cell lung carcinomas induced by expression of GTPase-deficient G 16. J Biol Chem 271, 349-354 PMID 8550585</ref> This is when agonists activate signaling pathways at different distinct intensities. In his work with stem cells, they defined a mutation that captured self-renewing tissue stem cell in a permanent state of [[Epithelial–mesenchymal transition|EMT]].<ref>Vincent Jordan, N., Prat, A., Abell, A.N., Zawistowski, J.S., Sciaky, N., Karginova, O.A., Zhou., B, Golitz, B.T., Perou, C.M., Johnson, G.L.. (2013) SWI/SNF Chromatin-remodeling Factor Smarcd3/Baf60c Controls EMT by Inducing Wnt5a Signaling. Mol Cell Biol 33, 3011-3025. PMC3719671</ref> The lab has also made advancements in Adaptive Kinome Programming. They defined the adaptive bypass mechanisms that result in the lack of durable responses to targeted kinase inhibitors.<ref>Johnson, G.L., Stuhlmiller, T.J., Angus, S.P., Zawistowski, J.S., Graves, L.M. (2014) Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF-MEK-ERK Pathway in Cancer. Clin Cancer Res. 20: 2516-2522 PMC4024346</ref> Overall, Johnson has over 300 published papers<ref>My Bibliography - NCBI (nih.gov)</ref>


== Awards and Recognition ==
== Awards and recognition ==
In 2018, Johnson was awarded the Hyman L. Battle Award for Cancer Research<ref name=":0" />. In 2008, he won a Merit Award from the National Institute of General Medical Sciences<ref>{{Cite web|title=NIGMS MERIT Awards|url=https://www.nigms.nih.gov/research/pages/meritawards.aspx|access-date=2020-12-01|website=www.nigms.nih.gov}}</ref>
In 2018, Johnson was awarded the Hyman L. Battle Award for Cancer Research.<ref name=":0" /> In 2008, he won a Merit Award from the [[National Institute of General Medical Sciences]].<ref>{{Cite web|title=NIGMS MERIT Awards|url=https://www.nigms.nih.gov/research/pages/meritawards.aspx|access-date=2020-12-01|website=www.nigms.nih.gov}}</ref>


== References ==
== References ==
<references />
<references />
{{User sandbox}}
<!-- EDIT BELOW THIS LINE -->


== Gary L. Johnson ==
== External links ==
*{{google scholar id|DunBAYMAAAAJ}}


{{Authority control}}
{{AfC submission|||ts=20210223153949|u=Ferreiramy|ns=2}}

{{DEFAULTSORT:Johnson, Gary L.}}
[[Category:Year of birth missing (living people)]]
[[Category:Living people]]
[[Category:California State University, Northridge alumni]]
[[Category:University of Colorado School of Medicine alumni]]
[[Category:American pharmacologists]]
[[Category:University of San Francisco alumni]]
[[Category:University of North Carolina at Chapel Hill faculty]]
[[Category:American cancer researchers]]

Latest revision as of 01:57, 2 July 2024

Gary L. Johnson
CitizenshipAmerican
OccupationProfessor
Board member ofAmerican Association for Cancer Research (AACR)
AwardsKenan Distinguished Professor Hyman L. Battle Distinguished Cancer Research Award
Academic background
Alma materCalifornia State University, Northridge

University of Colorado Medical School

University of California, San Francisco
Academic work
DisciplinePharmacology, Cellular Biology,

Gary L. Johnson is an American scientist and Professor recognized for his work with oncogenes and stem cells in the fields of molecular pharmacology and cancer cell biology. His other research interests include signaling networks controlling cell function and disease and the behavior of the kinome en masse in cancer.[1]

Johnson is a past Kenan Distinguished Professor, chair of the UNC Chapel Hill Department of Pharmacology, and a member of the UNC Lineberger Comprehensive Cancer Center.

Education

[edit]

Johnson earned his B.A. in Biology in 1971 at Cal State Northridge,where he graduated Magna Cum Laude, and his Ph.D. in Pharmacology in 1976 at the University of Colorado Medical School.[2] He then completed his PostDoc in 1979 at the University of California, San Francisco. He served as the chair of the Department of Pharmacology at UNC Chapel Hill from 2003 to 2017 and was a Kenan Distinguished Professor from 2011 to 2019. During his time in education, Johnson trained over 80 postdoctoral fellows and PhD students. Now, Johnson works as the co-director of the Program in Molecular Therapeutics for the Lineberger Comprehensive Cancer Center and director of the Human Genome RNAi/CRISPR Screening Facility.[1]

Work

[edit]

From 1994 to 1999, Johnson served as the Director of Cell Biology for Cadus Pharmaceuticals Inc. He worked four years as a consultant for Atherogenics, Inc. He was a co-founder of KinoDyn, Inc., a biotech company located in Chapel Hill, NC.[3]

Research

[edit]

Johnson has made many contributions to the fields of molecular pharmacology and cell biology. In the early 90s, his laboratories demonstrated that oncogenes, such as Ras and Src, activated the MAPK, ERK1/2. This research defined the MAPK signaling network as part a large network of MAP3Ks, MAP2Ks, and MAPKs. They defined the role MAPKs in proliferation, apoptosis, migration, and invasion.[4] His laboratory published 250 MAPK network related papers. His lab was one to demonstrate that agonists targeting the same GPCR have "biased agonism" and "asymmetric signaling."[5] This is when agonists activate signaling pathways at different distinct intensities. In his work with stem cells, they defined a mutation that captured self-renewing tissue stem cell in a permanent state of EMT.[6] The lab has also made advancements in Adaptive Kinome Programming. They defined the adaptive bypass mechanisms that result in the lack of durable responses to targeted kinase inhibitors.[7] Overall, Johnson has over 300 published papers[8]

Awards and recognition

[edit]

In 2018, Johnson was awarded the Hyman L. Battle Award for Cancer Research.[1] In 2008, he won a Merit Award from the National Institute of General Medical Sciences.[9]

References

[edit]
  1. ^ a b c "Gary L. Johnson". UNC Lineberger. Retrieved 2020-10-07.
  2. ^ "Gary Johnson: Speaking From Experience". www.science.org. 14 October 2005. Retrieved 2022-09-13.
  3. ^ Company profile dnb.com
  4. ^ Gallego, C., Gupta, S.K., Heasley, L.E., Qian, N.-X. and Johnson, G.L. (1992) Mitogen-activated protein kinase activation resulting from selective oncogene expression in NIH 3T3 and Rat 1a cells. Proc Natl Acad Sci USA 89, 7355-7359 PMC50199
  5. ^ Heasley, L.E., Zamarripa, J., Storey, B., Helfrich, B., Mitchell, F.M., Bunn, Jr., P.A. and Johnson, G.L. (1996) Discordant signal transduction and growth inhibition of small cell lung carcinomas induced by expression of GTPase-deficient G 16. J Biol Chem 271, 349-354 PMID 8550585
  6. ^ Vincent Jordan, N., Prat, A., Abell, A.N., Zawistowski, J.S., Sciaky, N., Karginova, O.A., Zhou., B, Golitz, B.T., Perou, C.M., Johnson, G.L.. (2013) SWI/SNF Chromatin-remodeling Factor Smarcd3/Baf60c Controls EMT by Inducing Wnt5a Signaling. Mol Cell Biol 33, 3011-3025. PMC3719671
  7. ^ Johnson, G.L., Stuhlmiller, T.J., Angus, S.P., Zawistowski, J.S., Graves, L.M. (2014) Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF-MEK-ERK Pathway in Cancer. Clin Cancer Res. 20: 2516-2522 PMC4024346
  8. ^ My Bibliography - NCBI (nih.gov)
  9. ^ "NIGMS MERIT Awards". www.nigms.nih.gov. Retrieved 2020-12-01.
[edit]
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Gary_L._Johnson&oldid=1232120422"